胃部・食道胃接合部腺癌市場：アメリカの治療薬市場...市場調査レポートについてご紹介

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Biomarkers/Targets of Interest
3.2 Staging
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening
4.1.2 Diagnosis
4.1.3 Treatment Guidelines and Leading Prescribed Drugs
4.1.4 Clinical Practice
4.2 US
4.2.1 Screening and Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 HER2-Targeted Therapy
5.2.1 Herceptin (trastuzumab)
5.3 Angiogenesis Inhibitors
5.3.1 Cyramza (ramucirumab)
5.3.2 Aitan (apatinib)
5.4 Chemotherapies
5.4.1 TS-1 (tegafur, gimeracil, oteracil)
5.4.2 Abraxane (nab-paclitaxel)
6 Unmet Need and Opportunity
6.1 Overview
6.2 First-Line Therapy for HER2-Negative Patients
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 New Molecular Targets for Targeted Therapies
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Effective Perioperative and Postoperative Therapies
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 More Efficacious HER2-Targeted Therapies
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Peritoneal Metastases
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Better Clinical Trial Design
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
6.8 Early Detection of Gastric and Gastroesophageal Adenocarcinomas
6.8.1 Unmet Need
6.8.2 Gap Analysis
6.8.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Phase III Clinical Development
7.3 HER2-Targeted Therapies
7.3.1 Kadcyla (T-DM1; trastuzumab emtansine)
7.3.2 Perjeta (pertuzumab)
7.4 Immune Checkpoint Inhibitors
7.4.1 Keytruda (pembrolizumab)
7.4.2 Opdivo (nivolumab)
7.5 Further Strategies for G/GEJAC Treatment
7.5.1 Napabucasin
7.5.2 Lynparza (olaparib)
7.5.3 Nimotuzumab
7.5.4 TAS-118
7.6 Early/Near-Phase III Pipeline Drugs
7.6.1 GS-5745
7.6.2 Masitinib
7.7 Promising Drugs in Early-Stage Development
7.7.1 Immune Checkpoint Inhibitors
7.7.2 MET-Targeting Drugs
7.7.3 Antibody-Drug Conjugates
7.8 Biosimilars
8 Market Outlook
8.1 US
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers – US
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed G/GEJAC Patients
9.4.2 Percent of Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Primary Research – Key Opinion Leaders Interviewed for this Report
9.6 Primary Research – High-Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Therapy Area Director
9.7.3 Epidemiologist
9.7.4 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer